argenx Elevates COO Karen Massey to CEO, Authorizes 10% Share Issuance
ARGX•Shareholders representing 90.9% of argenx’s share capital approved appointing COO Karen Massey as CEO and co-founder Tim Van Hauwermeiren as board chair. The meeting authorized issuing new shares equal to 10% of outstanding capital over 18 months and approved the 2025 remuneration and annual reports.
1. Leadership Transition
argenx’s Board appointed Chief Operating Officer Karen Massey as Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren, who becomes board chair. Massey joined the company in March 2023 and has driven execution of the company’s immunology pipeline and long-term growth strategy.
2. Shareholder Voting and Governance Approvals
The Annual General Meeting saw 90.9% of share capital represented, with shareholders unanimously approving the 2025 remuneration report, annual accounts, profit allocation and the reappointment of non-executive directors Ana Céspedes, Camilla Sylvest and Pam Klein for terms of two to four years.
3. Authorization of New Share Issuance
Shareholders granted the board authority to issue new shares and subscription rights representing up to 10% of current outstanding capital over the next 18 months, a move that could support funding of pipeline expansion but may dilute existing holdings.
